The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy
August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for the treatment of adult patients..
Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
June 2024: Pembrolizumab (Keytruda, Merck) has been authorized by the Food and Drug Administration for the treatment of adult patients with primary, advanced, or recurrent endometrial cancer. The treatment involves the u..
Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer
June 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for the tr..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Ventana Medical Systems
Pembrolizumab is approved for advanced endometrial carcinoma
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair de..
Eisai, KEYTRUDA, Lenvatinib, Lenvima, Merck, NCT03517449, Pembrolizumab
Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer
August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients with advanced endometrial carcinoma that is not microsatellite instabi..
Jemperli, platinum-containing regimen, RECIST
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, a..